argenx SE (NASDAQ:ARGX) Shares Purchased by Allspring Global Investments Holdings LLC

Posted by on Apr 5th, 2023

Allspring Global Investments Holdings LLC lifted its position in argenx SE (NASDAQ:ARGX – Get Rating) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,501 shares of the company’s stock after purchasing an additional 4,204 shares during the period. Allspring Global Investments Holdings LLC’s holdings in argenx were worth $27,844,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ARGX. JPMorgan Chase & Co. lifted its stake in shares of argenx by 143.0% in the 1st quarter. JPMorgan Chase & Co. now owns 1,577 shares of the company’s stock valued at $497,000 after purchasing an additional 928 shares during the period. Raymond James & Associates increased its holdings in argenx by 19.4% in the 1st quarter. Raymond James & Associates now owns 4,534 shares of the company’s stock worth $1,430,000 after acquiring an additional 738 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in argenx by 46.0% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 3,544 shares of the company’s stock worth $1,117,000 after acquiring an additional 1,116 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in argenx by 4.4% in the 1st quarter. Bank of New York Mellon Corp now owns 6,447 shares of the company’s stock worth $2,033,000 after acquiring an additional 271 shares in the last quarter. Finally, US Bancorp DE increased its holdings in argenx by 43.0% in the 1st quarter. US Bancorp DE now owns 1,798 shares of the company’s stock worth $566,000 after acquiring an additional 541 shares in the last quarter. 57.29% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Up 2.0 %

Shares of ARGX stock opened at $367.47 on Wednesday. The company’s 50-day moving average price is $365.09 and its 200-day moving average price is $371.19. The stock has a market cap of $20.39 billion, a price-to-earnings ratio of -27.99 and a beta of 0.74. argenx SE has a twelve month low of $267.35 and a twelve month high of $407.93.

argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings results on Thursday, March 2nd. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($3.08) by $2.38. The firm had revenue of $182.12 million for the quarter, compared to analysts’ expectations of $177.11 million. argenx had a negative net margin of 159.36% and a negative return on equity of 49.07%. As a group, equities research analysts predict that argenx SE will post -8.99 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Stifel Nicolaus boosted their price target on shares of argenx from $471.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, December 22nd. JMP Securities boosted their price target on shares of argenx from $443.00 to $448.00 and gave the stock a “market outperform” rating in a report on Friday, March 3rd. SVB Securities upped their target price on shares of argenx from $430.00 to $435.00 in a report on Friday, March 3rd. SVB Leerink upped their target price on shares of argenx from $430.00 to $435.00 and gave the stock an “outperform” rating in a report on Friday, March 3rd. Finally, Piper Sandler upped their target price on shares of argenx from $465.00 to $475.00 and gave the stock an “overweight” rating in a report on Thursday, February 23rd. One research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $454.64.

argenx Company Profile

(Get Rating)

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

See Also

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX – Get Rating).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.